SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parfitt AM 2002 High bone turnover is intrinsically harmful: Two paths to a similar conclusion. The Parfitt view. J Bone Miner Res 17: 15581559.
  • 2
    Ravn P, Rix M, Andreassen H, Clemmesen B, Bidstrup M, Gunnes M 1997 High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women. Calcif Tissue Int 60: 255260.
  • 3
    Akesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, Gardsell P, Obrant KJ 1995 Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study of women. J Bone Miner Res 10: 18231829.
  • 4
    Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11: 15311538.
  • 5
    Johnell O, Oden A, de Laet C, Garnero P, Delmas PD, Kanis JA 2002 Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 13: 523526.
  • 6
    Eriksen EF 1986 Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 7: 379408.
  • 7
    Seeman E 2003 Reduced bone formation and increased bone resorption: Rational targets for the treatment of osteoporosis. Osteoporos Int 14 (Suppl 3): S2S8.
  • 8
    Heaney RP 2003 Is the paradigm shifting? Bone 33: 457465.
  • 9
    Russell RG, Rogers MJ 1999 Bisphosphonates: From the laboratory to the clinic and back again. Bone 25: 97106.
  • 10
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280: 20772082.
  • 11
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 15351541.
  • 12
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 41184124.
  • 13
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 14371443.
  • 14
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 14751480.
  • 15
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687694.
  • 16
    Turner CH 2002 Biomechanics of bone: Determinants of skeletal fragility and bone quality. Osteoporos Int 13: 97104.
  • 17
    Dempster DW 2003 Bone microarchitecture and strength. Osteoporos Int 14 (Suppl 5): 5456.
  • 18
    Delmas PD 2002 Treatment of postmenopausal osteoporosis. Lancet 359: 20182026.
  • 19
    Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli JM, Darby AJ, Tregear GW, Parsons JA 1976 Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1: 10351038.
  • 20
    Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. BMJ 280: 13401344.
  • 21
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350: 550555.
  • 22
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 14341441.
  • 23
    Orwoll E, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich G 2003 The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone mineral density in men with osteoporosis. J Bone Miner Res 18: 917.
  • 24
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104: 439446.
  • 25
    Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM 1999 Anabolic effects of human biosynthetic parathyroid hormone fragment (1–34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 14: 536545.
  • 26
    Sato M, Zeng GQ, Turner CH 1997 Biosynthetic human parathyroid hormone (1–34) effects on bone quality in aged ovariectomized rats. Endocrinology 138: 43304337.
  • 27
    Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM 2001 Intermittently administered human parathyroid hormone(1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16: 157165.
  • 28
    Brommage R, Hotchkiss CE, Lees CJ, Stancill MW, Hock JM, Jerome CP 1999 Daily treatment with human recombinant parathyroid hormone-(1–34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 84: 37573763.
  • 29
    McClung MR, Miller PD, Civitelli R, Warren ML, Greenspan SL, Tamayo JA, Donley DW, San Martin J 2003 Distinctive effects of teriparatide [rhPTH(1–34)] and alendronate on bone turnover and lumbar spine bone density in women with osteoporosis. Osteoporos Int 13: S18.
  • 30
    McClung M, Miller P, Civitelli R, Warren M, Greenspan S, Haddock L, Tamayo J, Donley D, San Martin J 2003 Differential effects of teriparatide and alendronate on markers of bone remodeling and areal and volumetric bone density in women with osteoporosis. J Bone Miner Res 18: S1S40.
  • 31
    Meunier PJ, Arlot ME, San Martin J, Boivin G, Donley DW, Correa-Rotter R, Jasgui S, Tamayo J, Eriksen EF 2003 Diverging effects of teriparatide and alendronate on bone formation in postmenopausal women with osteoporosis. A histomorphometric study after 6 months of therapy. Calcif Tissue Int 72: 407.
  • 32
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595610.
  • 33
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Teriparatide [recombinant human parathyroid hormone (1–34)] improves both cortical and cancellous bone structure. J Bone Miner Res 18: 19321941.
  • 34
    Roux JP, Arlot ME, Gineyts E, Meunier PJ, Delmas PD 1995 Automatic-interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinoline. Bone 17: 153156.
  • 35
    Boivin G, Meunier PJ 2002 The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 70: 503511.
  • 36
    Boivin G, Meunier PJ 2003 Methodological considerations in measurement of bone mineral content. Osteoporos Int 14 (Suppl 5): 2228.
  • 37
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16: 18461853.
  • 38
    Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment. J Clin Endocrinol Metab 88: 11501156.
  • 39
    Hernandez CJ, Beaupre GS, Marcus R, Carter DR 2001 A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 29: 511516.
  • 40
    Arlot ME, Delmas PD, Chappard D, Meunier PJ 1990 Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: Comparison with normal postmenopausal women. Osteoporos Int 1: 4149.
  • 41
    Martin TJ 2004 Does bone resorption inhibition affect the anabolic response to parathyroid hormone? Trends Endocrinol Metab 15: 4950.
  • 42
    Ma YL, Donley DW, Eriksen EF 2003 Characteristics of modeling and remodeling osteons after teriparatide treatment. Bone 32: S225.
  • 43
    Eriksen EF, Donley DW, Ma LY 2003 Teriparatide increases the width of modeling and remodeling osteons at the trabecular and endosteal envelope. Calcif Tissue Int 72: 329.
  • 44
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 12071215.
  • 45
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 12161226.
  • 46
    Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745751.
  • 47
    Ruff CB, Hayes WC 1982 Subperiosteal expansion and cortical remodeling of the human femur and tibia with aging. Science 217: 945948.
  • 48
    Power J, Loveridge N, Rushton N, Parker M, Reeve J 2003 Evidence for bone formation on the external “periosteal” surface of the femoral neck: A comparison of intracapsular hip fracture cases and controls. Osteoporos Int 14: 141145.
  • 49
    Heaney RP 2003 Remodeling and skeletal fragility. Osteoporos Int 14: S12S15.
  • 50
    Boivin G, Lips P, Ott SM, Harper KD, Sarkar S, Pinette KV, Meunier PJ 2003 Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 88: 41994205.
  • 51
    Eriksen EF, Melsen F, Sod E, Barton I, Chines A 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31: 620625.